The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma

Melphalan (L-PAM) has been an integral part of multiple myeloma (MM) treatment as a conditioning regimen before stem cell transplant (SCT). After initial response, most treated patients experience relapse with an aggressive phenotype. Increased glutathione (GSH) in MM may mediate resistance to L-PAM...

Descripción completa

Detalles Bibliográficos
Autores principales: Tagde, A, Singh, H, Kang, M H, Reynolds, C P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219442/
https://www.ncbi.nlm.nih.gov/pubmed/25036800
http://dx.doi.org/10.1038/bcj.2014.45

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219442/
https://www.ncbi.nlm.nih.gov/pubmed/25036800
http://dx.doi.org/10.1038/bcj.2014.45

Ejemplares similares